# Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

Source: https://onco.cc/trials/nct03925935/  
OnCo record `nct03925935` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of AB-205 run by Angiocrine Bioscience, completed.

## Summary

Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation is a phase 1 interventional study registered as NCT03925935 by Angiocrine Bioscience, with 42 participants enrolled, started 2019-05-07. Conditions recorded: Hodgkin Lymphoma and Non-hodgkin Lymphoma. Interventions recorded: AB-205.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03925935
- Phase: 1
- Setting: A Phase 1, Open Label, Non-randomized, Multi-Center Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation
- Sponsor: Angiocrine Bioscience
- Enrolled: 42

## Sources

- ClinicalTrials.gov NCT03925935: https://clinicaltrials.gov/study/NCT03925935

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [AB-205](https://onco.cc/drugs/ab-205/)
- companies: [Angiocrine Bioscience](https://onco.cc/companies/angiocrine-bioscience/)

---
JSON: https://onco.cc/api/v1/entities/nct03925935.json